NCM
Nantahala Capital Management Portfolio holdings
AUM
$1.68B
1-Year Est. Return
115.06%
This Fund
S&P 500
1 Year Est. Return
+115.06%
AUM
$1.62B
AUM Growth
+$206M
(+15%)
Holding
167
Top Buys
| 1 | +$17.3M | |
| 2 | +$15.7M | |
| 3 | +$12M | |
| 4 |
Evolus
EOLS
|
+$11.9M |
| 5 |
LBRX
LB Pharmaceuticals
LBRX
|
+$10.7M |
Top Sells
| 1 | +$56.7M | |
| 2 | +$19M | |
| 3 | +$18.8M | |
| 4 |
THRD
Third Harmonic Bio
THRD
|
+$16M |
| 5 |
Gogo Inc
GOGO
|
+$15.3M |
Sector Composition
| 1 | Healthcare | 69.32% |
| 2 | Consumer Discretionary | 12.89% |
| 3 | Financials | 5.23% |
| 4 | Communication Services | 4.07% |
| 5 | Industrials | 2.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
enVVeno Medical
NVNO
$8.49M
| – | – |
-16,990
|
|
||
152
Regeneron Pharmaceuticals
REGN
$81B
| – | – |
0
|
|
||
153
RH
RH
$2.6B
| – | – |
0
|
|
||
154
Rezolute
RZLT
$298M
| – | – |
-2,291,395
|
|
||
155
Syndax Pharmaceuticals
SNDX
$1.85B
| – | – |
-754,503
|
|
||
156
Transact Technologies
TACT
$34.9M
| – | – |
-15,046
|
|
||
157
Teva Pharmaceuticals
TEVA
$36.3B
| – | – |
0
|
|
||
|
THRD
158
DELISTED
Third Harmonic Bio
THRD
| – | – |
-2,938,700
|
|
||
|
THTX
159
DELISTED
Theratechnologies
THTX
| – | – |
-2,422,563
|
|
||
|
TRML
160
DELISTED
Tourmaline Bio
TRML
| – | – |
-558,187
|
|
||
161
UroGen Pharma
URGN
$1.18B
| – | – |
-6,703
|
|
||
|
VERV
162
DELISTED
Verve Therapeutics
VERV
| – | – |
-331,437
|
|
||
163
Viatris
VTRS
$17.2B
| – | – |
0
|
|
||
164
State Street SPDR S&P Biotech ETF
XBI
$8.57B
| – | – |
0
|
|
||
165
Exagen
XGN
$64.5M
| – | – |
-61,186
|
|
||
|
YMAB
166
DELISTED
Y-mAbs Therapeutics
YMAB
| – | – |
-351,878
|
|
||
|
OKUR
167
OnKure Therapeutics
OKUR
$201M
| – | – |
-54,208
|
|